Description: BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.
Home Page: www.biovaxys.com
905 West Pender Street
Vancouver,
BC
V6C 1L6
Canada
Phone:
604 262 8835
Officers
| Name | Title |
|---|---|
| Mr. James Christopher Passin | Co-Founder, CEO & Director |
| Mr. Kenneth E. Kovan | Co-Founder, Pres & COO |
| Dr. David Berd | Co-Founder & Chief Medical Officer |
| Mr. Craig William Loverock CA, CPA | Chief Financial Officer |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.5319 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | October |
| Full Time Employees: | 0 |